Sector News

Chinese buyer resurrects US Boehringer plant

November 3, 2014
Life sciences
Chinese company UniTao has agreed to buy a Boehringer Ingelheim manufacturing site in Petersburg, US, which was scheduled to be closed by the end of the year with the loss of 240 jobs.
 
UniTao will use the active pharmaceutical ingredient (API) manufacturing facility site to make APIs for global distribution, and intends to employ up to 376 people. The company has indicated that the availability of a skilled workforce was a favourable factor in its decision to buy the site.
 
By Phillip Broadwith
 

comments closed

Related News

September 13, 2024

MedTrace accelerates Phase III trial and announces appointment of Nicholas Borys as Chief Medical Officer

Life sciences

Pharma and medical imaging company MedTrace announced the appointment of Nicholas Borys, M.D., as Chief Medical Officer (CMO). Dr. Borys is a skilled and experienced healthcare executive with over 25 years experience in advancing portfolios of novel therapies across diverse indications in cardiovascular, cancer, and central nervous system disease.

September 13, 2024

Eli Lilly to invest $1.8bn in manufacturing capacity in Ireland

Life sciences

Eli Lilly and Company has announced a significant expansion of its manufacturing presence in Ireland, with a $1bn investment earmarked for its Limerick site. The move is aimed at boosting the company’s production of biologic active ingredients, including those for its approved Alzheimer’s treatment.

September 13, 2024

Lonza completes expansion of microbial manufacturing facility

Life sciences

Lonza recently announced that it has completed a planned expansion of the mid-scale microbial manufacturing facility at its Visp, Switzerland site. This multi-product facility was recently granted a GMP license, allowing cGMP manufacturing and release of biologics produced using microbial fermentation.